COP vs DHR: Which Is the Better Buy?
Side-by-side comparison of ConocoPhillips and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-23.
ConocoPhillips · Energy
$127.53
+32.1% upside to fair value
Med Conviction
Grade B
VS
Danaher Corporation · Healthcare
$221.12
+29.6% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
COP has more upside to fair value
(+32.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
COP |
DHR |
| Current Price |
$127.53 |
$221.12 |
| Fair Value Estimate |
$168.50 |
$286.52 |
| Upside to Fair Value |
+32.1%
|
+29.6%
|
| Market Cap |
$155.4B |
$155.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
6.2x
|
24.8x
|
| Price / Sales |
2.5x
|
6.2x
|
| Price / FCF |
7.9x
|
28.5x
|
| Revenue Growth YoY |
+36.8%
|
+5.5%
|
| Gross Margin |
27.7%
|
58.5%
|
| Operating Margin |
21.9%
|
20.4%
|
| Return on Equity |
14.3%
|
7.7%
|
| Dividend Yield |
2.63% |
0.65% |
| FCF Yield |
12.66%
|
3.51%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
ConocoPhillips is a global exploration and production company with a portfolio spanning unconventional North American shale, conventional international assets, LNG ventures, and Canadian oil sands, run by a new leadership team after Andy O'Brien became CEO on September 1, 2026. The business quality is medium: it generates substantial cash, with $16.15 in free cash flow per share and a 14.3% retur…
Danaher is a diversified life-sciences and diagnostics platform spanning three segments: Life Sciences (mass spectrometers, flow cytometry, genomics, bioprocess technologies), Diagnostics (chemistry, immunoassay, microbiology, hematology, molecular and pathology systems), and Environmental & Applied Solutions (water quality and product-identification instrumentation). The business quality is high…
Accumulation Zones
| Metric |
COP |
DHR |
| Zone Low |
$126.38 |
$214.89 |
| Zone High |
$143.22 |
$243.54 |
| In Buy Zone? |
Yes
|
Yes
|